Comparative Pharmacology
Head-to-head clinical analysis: QVAR REDIHALER versus VENTAIRE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QVAR REDIHALER versus VENTAIRE.
QVAR REDIHALER vs VENTAIRE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
Ventaire (broxaterol) is a selective beta-2 adrenergic receptor agonist that stimulates adenyl cyclase, increasing intracellular cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation.
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
1-2 inhalations (25-50 mcg salmeterol and 100-200 mcg fluticasone) twice daily via inhalation aerosol.
None Documented
None Documented
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Terminal elimination half-life is 8-12 hours; clinical context: steady-state reached in 2-3 days, trough levels predict efficacy.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Primarily renal excretion of unchanged drug (70-80%) and metabolites (10-15%); biliary/fecal excretion accounts for <5%.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid